<DOC>
	<DOCNO>NCT02129231</DOCNO>
	<brief_summary>Aims : To evaluate effect ezetimibe/simvastatin rosuvastatin oxidative stress mitochondrial function patient DPN . Methods : We perform randomize , double-blinded , placebo-controlled phase II clinical trial adult patient type 2 Diabetes Mellitus ( T2DM ) Diabetic Polyneuropathy ( DPN ) evaluate composite score nerve conduction study ( NCS ) , HBA1C &lt; 12 % ( 108 mmol/mol ) , previous exclusion neuropathy . Ninety-eight person T2DM allocate 1:1:1 either placebo , ezetimibe/simvastatin 10/20 mg rosuvastatin 20 mg 16 week , healthy control ( randomize ) include comparison . Primary outcome lipid peroxidation ( LPO ) , nitric oxide ( NO ) , total antioxidant capacity ( TAC ) ; secondary clinical , NCS metabolic parameter . Results express mean ± standard deviation ( SD ) standard error mean ( SEM ) , frequency percentage . Non-parametric analysis use .</brief_summary>
	<brief_title>Statins Oxidative Stress Mitochondrial Function Diabetic Polyneuropathy</brief_title>
	<detailed_description>Introduction Nerve dysfunction system patient diabetes know diabetic neuropathy consider prevalent microvascular complication -up 60 % - type 2 Diabetes Mellitus ( T2DM ) subject . Diabetic polyneuropathy ( DPN ) comprise ≈70 % case . Its diagnosis establish mean validate score base clinical feature abnormal nerve conduction study ( NCS ) . Pathophysiologic finding include loss multifocal focal nerve fiber secondary axonal degeneration segmental demyelinization , basically due oxidative stress induce chronic hyperglycemia , lead neural apoptosis . Other mechanism involve peripheral nerve injure nitrosative stress induce nitric oxide ( NO ) . Ezetimibe diminish cholesterol ester content chylomicron reduce liver cholesterol intake consequence increase LDL uptake plasma depuration ; monotherapy reduces LDL-C 17 % . When combined simvastatin , cholesterol reduction potentially increase ; furthermore , pleiotropic effect statin include increase nuclear factor kappa B activity amelioration superoxide ion 12 week treatment . Another hydroxy-methyl-glutaryl coenzyme A inhibitor , rosuvastatin , antioxidant effect act free radical carrier diminish mitochondrial cellular lipid peroxidation ( LPO ) production . We conduct study evaluate effect ezetimibe/simvastatin rosuvastatin oxidative stress patient DPN . Methods Study design A randomized , double blind , placebo control phase II clinical trial perform Clinic Experimental Therapeutics Institute , University Guadalajara , Mexico . Subjects assign three group treatment block parallel sequence 1:1:1 randomize computer-based list , generate different researcher unaware drug give . Patients divide : control group receive placebo , ezetimibe/simvastatin rosuvastatin daily single dose 16 week . The selection period perform February 2012 January 2013 . We select 5 non-randomized healthy subject ( HS ) blood bank compare oxidative stress status . Study population Inclusion criterion ≥18 year old , T2DM accord American Diabetes Association DPN Dyck et . al.3 criterion , HbA1c &lt; 12 % , informed consent sign . They exclude renal hepatic failure , pregnant breastfeeding , neuropathy ( alcohol-induced , radiculopathy , autoimmune , cancer-related ) , eliminate lack treatment adherence ( &lt; 80 % drug intake ) , severe adverse drug reaction and/or serious health illness . Patients select invitation forum ; outpatient recruit primary care clinic ; database collect previously Institute February 2010 2012 . Patients instructed take drug night time every day , follow : placebo 100 mg , ezetimibe/simvastatin 10/20 mg , rosuvastatin 20 mg. All drug similar physical characteristic present dark vial , carefully fill another group researcher , place respective tag patient code . Also , patient provide diary would write date time drug administration , drug adverse reaction felt . Such information collect registered every 4 week . Primary outcome oxidative stress marker LPO , NO , TAC 16 week intervention . Secondary outcomes clinical , NCS metabolic [ fast glucose , HbA1c , total cholesterol , high low density lipoprotein ( HDL , LDL ) , triglycerides ] parameter . Safety profile assess drug adverse reaction , renal ( urea , creatinin ) , hepatic [ ( alamin- aspartate-aminotransferase , gama-glutamyltransferase , bilirubins phosphokinase ] laboratory variable . Oxidative stress mitochondrial function marker LPO measure accord kit specification ( Oxford Biomedical Research Inc. , FR12 ) , 200 μL serum process chromogen substance reacts malondialdehyde ( MDA ) 4-hydroxy-alkenals ( HNA ) , absorbance measure 586 nm , result express nmol/mL . Previous deproteinization sample , perform colorimetric determine concentration NO 85 µL serum ( Nitric Oxide Assay Kit , User protocol 482650 ) , result express pmol/mL . Total antioxidant capacity ( TAC ) realize 200 µL serum , obtain value millimole ( mM ) equivalent uric acid ( Total Antioxidant Power Kit , No . 02090130 , Oxford Biomedical Research® ) . Clinical nerve conduction variable Neuropathic symptom ( NSS ) disability score ( NIS ) describe Dyck , et . al . obtain physical examination anamnesis . We also measure latency , duration , amplitude motor nerve conduction velocity fibula , tibial , median ulnae nerve , sensitivity parameter sural , median ulnae nerve , require American Association Electrodiagnostic Medicine . Ethical consideration The study approve Research Ethics Committee Health Science University Center , University Guadalajara , Mexico . Identification code assign participant guarantee patient confidentiality , informed consent form sign enter protocol , accord national international law , also stipulate Helsinki Statements ( http : //www.wma.net/es/30 publications/ 10 policies/b3/17c.pdf , access January 2011 ) . Statistical analysis The sample size obtain clinical study design formula take account difference change 0.05 nmol/mL LPO , 95 % confidence interval , 80 % potency , two-tailed p &lt; 0.05 , result 21 group . Quantitative variable express mean ± standard deviation . Kolmogorov-Smirnov Shapiro-Wilk test perform determine non-parametric distribution variable . Friedman Wilcoxon test realize measurement , Kruskal-Wallis Mann-Whitney´s U post-hoc analysis group comparison . Qualitative variable express frequency percentage . Chi square test use evaluate difference dichotomy variable treatment , group comparison determine Fisher´s exact test χ2 need . Significance level establish p value &lt; 0.05 .</detailed_description>
	<mesh_term>Polyneuropathies</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<mesh_term>Ezetimibe , Simvastatin Drug Combination</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<mesh_term>Magnesium Oxide</mesh_term>
	<criteria>18 year old old Type 2 Diabetes Mellitus accord American Diabetes Association Diabetic Polyneuropathy Dyck et . al . criterion HbA1c &lt; 12 % Informed consent sign Renal hepatic failure Pregnant breastfeeding Other neuropathy ( alcoholinduced , radiculopathy , autoimmune , cancerrelated )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>ezetimibe/simvastatin</keyword>
	<keyword>rosuvastatin</keyword>
	<keyword>diabetic polyneuropathy</keyword>
	<keyword>oxidative stress</keyword>
	<keyword>mitochondrial dysfunction</keyword>
</DOC>